Patrice Rioux
Fondateur chez THIOGENESIS THERAPEUTICS, CORP.
Fortune : 3 M $ au 31/05/2024
Profil
Patrice P.
Rioux is the founder of Thiogenesis Therapeutics, Inc. (founded in 2016) where he holds the title of President, Chief Executive Officer & Director.
He is also the founder of Thiogenesis Therapeutics Corp.
(founded in 2018) where he holds the title of Chief Executive Officer & Non-Independent Director.
Currently, Dr. Rioux is the Chief Medical Officer at Monopar Therapeutics, Inc. (since 2016).
In the past, he has worked as Vice President-Medical Research at Repligen Corp., Chief Medical Officer at Edison Pharmaceuticals, Inc., Senior Vice President-Global Clinical Development at ArmaGen, Inc., Chief Medical Officer at FerroKin BioSciences, Inc., Chief Medical Officer at Horizon Pharmaceutical LLC, and Chief Medical Officer at Raptor Pharmaceuticals Corp.
(2009-2014) and Raptor Pharmaceuticals, Inc. (2009-2014).
Dr. Rioux obtained a doctorate degree from Faculté de Médecine Paris and an undergraduate degree from Pitié-Salpêtrière.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/02/2024 | 6 770 069 ( 16,29% ) | 3 M $ | 31/05/2024 | |
MONOPAR THERAPEUTICS INC
0,11% | 01/01/2024 | 18 433 ( 0,11% ) | 11 263 $ | 31/05/2024 |
Postes actifs de Patrice Rioux
| Sociétés | Poste | Début |
|---|---|---|
| MONOPAR THERAPEUTICS INC. | Directeur Technique/Scientifique/R&D | 01/12/2016 |
| THIOGENESIS THERAPEUTICS, CORP. | Fondateur | 01/01/2018 |
Thiogenesis Therapeutics, Inc.
 Thiogenesis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thiogenesis Therapeutics, Inc. engages in the development of novel compounds that are based on thiols, thiol derivatives or S-H groups. The company was founded by Patrice P. Rioux and Vincent P. Stanton and is headquartered in Belmont, MA. | Fondateur | 01/02/2016 |
Anciens postes connus de Patrice Rioux
| Sociétés | Poste | Fin |
|---|---|---|
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Directeur Technique/Scientifique/R&D | 01/10/2014 |
Raptor Pharmaceuticals, Inc.
 Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | Directeur Technique/Scientifique/R&D | 01/10/2014 |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Corporate Officer/Principal | - |
| RAPTOR PHARMACEUTICAL CORP | Directeur Technique/Scientifique/R&D | - |
FerroKin BioSciences, Inc.
 FerroKin BioSciences, Inc. Pharmaceuticals: MajorHealth Technology FerroKin BioSciences, Inc. offers clinical stage biotechnology services for iron chelator in the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was founded by Hugh Young Rienhoff, Jr. in 2007 and is headquartered in San Carlos, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de Patrice Rioux
| Faculté de Médecine Paris | Doctorate Degree |
| Pitié-Salpêtrière | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| REPLIGEN CORPORATION | Health Technology |
| MONOPAR THERAPEUTICS INC. | Health Technology |
| THIOGENESIS THERAPEUTICS, CORP. | Finance |
| Entreprise privées | 7 |
|---|---|
Edison Pharmaceuticals, Inc.
 Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edison Pharmaceuticals, Inc. developed drugs to treat mitochondrial diseases. It offers EPI-743 and EPI-A0001, an orally absorbed small molecules. The company was founded by Guy Miller in 2005 and was headquartered in Mountain View, CA. | Health Technology |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
FerroKin BioSciences, Inc.
FerroKin BioSciences, Inc. Pharmaceuticals: MajorHealth Technology FerroKin BioSciences, Inc. offers clinical stage biotechnology services for iron chelator in the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was founded by Hugh Young Rienhoff, Jr. in 2007 and is headquartered in San Carlos, CA. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | Health Technology |
Thiogenesis Therapeutics, Inc.
Thiogenesis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thiogenesis Therapeutics, Inc. engages in the development of novel compounds that are based on thiols, thiol derivatives or S-H groups. The company was founded by Patrice P. Rioux and Vincent P. Stanton and is headquartered in Belmont, MA. | Health Technology |
